New NIH external identity restrictions for NIH controlled access data
In support of recent security directives, NIH requires that we implement a technical update to enhance security measures focused on protecting data provided by NIH Controlled-Access Data Repositories (CADRs). Specifically, as of April 4, 2025, NIH is prohibiting access to and ending any remaining ongoing projects involving NIH CADRs and associated data by researchers and institutions located in countries of concern. These countries include China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela, consistent with EO 14117 and 28 CFR Part 202 “Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons.” Please see Guide Notice NOT-OD-25-083 for more details.
Relatedly, users with free email accounts (gmail, etc.) can no longer link to external identities such as NIH via the Profile page.
To make the Terra platform compliant by NIH's deadline, we have temporarily protected workspaces with potentially sensitive data. Access to the workspaces will once again open up to institutional/corporate Terra accounts with the proper authorization in the coming business days. Workspace data will not be affected in the meantime.
We apologize for any inconvenience.
Comments
1 comment
UPDATE: We now have a mechanism for manually adding institutional accounts to the federal_data_lockdown group so that users can regain access to their affected workspaces. If you would like your account added to the group, please contact support@terra.bio with the list of institutional accounts that need to be added.
NOTE: Because authorization domains cannot be removed from workspaces, free accounts (gmail, etc.) will not be able to regain access to any affected workspaces. We recommend deleting any associated cloud environments and persistent disks as they are no longer be accessible to those accounts. We deeply apologize for this disruption.
Please contact support@terra.bio if you have any questions or need to talk through a specific case.
Please sign in to leave a comment.